Original articleInfluence of tumor-associated macrophages and HLA class I expression according to HPV status in head and neck cancer patients receiving chemo/bioradiotherapy
Section snippets
Patients and tissues
Patients were selected from the former study cohort of 265 patients with histologically confirmed HNSCC, diagnosed between 2006 and 2012 in our institute (CRT: n = 194, BRT: n = 71) [17], [18]. Patients with stage III–IVb disease according to American Joint Committee on Cancer (AJCC)/International Union for Cancer Control (UICC) TNM classification 2010, received total radiation dose of 70 Gy, ≥2 cycles of concurrent cisplatin or ≥3 cycles of concurrent cetuximab were selected from the initial
Patient characteristics
The clinical and pathological characteristics of the patients included in this study are summarized in Table 1. The age of the study population ranged from 38 to 81 years (median, 60 years). Most (80%) patients were male. Sixty-four (67%) patients were never/former smokers and 31 (33%) were current smokers. With regard to HPV status, 27 (28%) patients had p16+ tumors and 68 (72%) had p16− tumors. All patients with p16+ tumors were oropharyngeal cancer (OPC) patients. Information on p16 status
Discussion
Tumor microenvironment consists of various host components including stromal cells, blood vessels and inflammatory infiltrates. It plays an important role in carcinogenesis, tumor progression and response to therapeutic interventions [21]. In the present study, although macrophage density and HLA class I expression were not identified as independent prognostic factors by multivariate analysis, subgroup analysis showed that intraepithelial macrophage density may play different roles in HPV+ as
Conflict of interest statement
None declared.
Acknowledgements
This work was supported by EU 7th framework program (ARTFORCE), No grant number is applicable; and China Scholarship Council (CSC) [201406105021 to D. O.].
References (43)
- et al.
Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients
Radiother Oncol
(2009) - et al.
Increased radiosensitivity of HPV-positive head and neck cancers: Molecular basis and therapeutic perspectives
Cancer Treat Rev
(2015) - et al.
Radiation therapy and immunotherapy: implications for a combined cancer treatment
Crit Rev Oncol Hematol
(2013) - et al.
Prognostic significance of macrophage polarization in early stage oral squamous cell carcinomas
Oral Oncol
(2016) - et al.
Immunological and clinical significance of HLA class I antigen processing machinery component defects in malignant cells
Oral Oncol
(2016) - et al.
Concurrent chemoradiotherapy with cisplatin or cetuximab for locally advanced head and neck squamous cell carcinomas: does human papilloma virus play a role?
Oral Oncol
(2016) - et al.
A comparison of clinically utilized human papillomavirus detection methods in head and neck cancer
Mod Pathol
(2011) - et al.
Tumor associated macrophages and neutrophils in cancer
Immunobiology
(2013) - et al.
Macrophages and therapeutic resistance in cancer
Cancer Cell
(2015) - et al.
Composition of inflammatory cells regulating the response to concurrent chemoradiation therapy for HPV (+) tonsil cancer
Oral Oncol
(2015)
Macrophage activation and polarization: nomenclature and experimental guidelines
Immunity
Immunological effects of conventional chemotherapy and targeted anticancer agents
Cancer Cell
Cetuximab ameliorates suppressive phenotypes of myeloid antigen presenting cells in head and neck cancer patients
J Immunother Cancer
Advances in radiotherapy of head and neck cancers
Curr Opin Oncol
Antitumor activity of pembrolizumab in biomarker-unselected patients with recurrent and/or metastatic head and neck squamous cell carcinoma: results from the phase Ib KEYNOTE-012 expansion cohort
J Clin Oncol
Human papillomavirus and survival of patients with oropharyngeal cancer
N Engl J Med
From monocytes to M1/M2 macrophages: phenotypical vs functional differentiation
Front Immunol
Infiltration of tumor-associated macrophages in human oral squamous cell carcinoma
Oncol Rep
CD163: a specific marker of macrophages in paraffin-embedded tissue samples
Am J Clin Pathol
Cancer-associated fibroblasts and CD163-positive macrophages in oral squamous cell carcinoma: their clinicopathological and prognostic significance
J Oral Pathol Med
Molecular mechanisms of HLA class I-mediated immune evasion of human tumors and their role in resistance to immunotherapies: HLA class I-mediated immune escape in tumors
HLA
Cited by (24)
Tumor associated macrophage in HPV<sup>+</sup> tumors: Between immunosuppression and inflammation
2023, Seminars in ImmunologyCitation Excerpt :Indeed, in a multivariate analysis, the authors showed that HPV-16 was required to increase intraepithelial macrophage density and HLA-class I expression, which leads to a better 5-year progression free survival in oropharyngeal patients (Table 1). However, the macrophage phenotype was not described in this study and therefore avoid any comparison with studies showing poorer prognosis in TAM infiltrated HNSCC [81]. Interestingly, HPV strains are able to favor certain types of TAM to rise and participate to the TME.
The prognostic role of tumor associated macrophages in squamous cell carcinoma of the head and neck: A systematic review and meta-analysis
2022, Oral OncologyCitation Excerpt :Pooled meta-analysis of the final ten studies investigating the relationship between CD68+TAMs and OS showed that a low number of CD68+TAMs correlated to a better OS (HR 1.36 95 %CI (1.07–1.72) P = .01, Figure 2b). In the univariate and multivariate pooled analysis, a total of four studies assessed CD68 in both tumor epithelium and tumor stroma.[21,25,37,43] Kikuchi et al. (2020) reported a trend that low CD68+TAMs correlated to better OS in the tumor epithelium.
Precision medicine and immuno-radiotherapy
2021, Cancer/RadiotherapieHigh throughput profiling of undifferentiated pleomorphic sarcomas identifies two main subgroups with distinct immune profile, clinical outcome and sensitivity to targeted therapies
2020, EBioMedicineCitation Excerpt :Amplification and detection steps were performed with an Ultraview kit and 3,3′-diaminobenzidine was used as a chromogen. CD68/CD163 double staining was performed on a Ventana Discovery Ultra platform (Roche, Bâle, Switzerland) and image analysis as described previously [13]. Image analysis was performed under the supervision of a pathologist (JA) to detect the density of CD8 and PD-1 positive cells in the tumor areas and the proportion of IDO1, CD68 and CD163 stained surface of tumor slides or spots, as previously described [14].